Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Am J Psychiatry. 2008 Mar;165(3):335-41; quiz 409. doi: 10.1176/appi.ajp.2007.07050776. Epub 2008 Feb 1.

Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder.

Author information

  • 1Obsessive-Compulsive Disorder Clinic, Department of Psychiatry, Massachusetts General Hospital, Boston, MA 02114, USA. wilhelm@psych.mgh.harvard.edu

Abstract

OBJECTIVE:

This study examined whether d-cycloserine, a partial agonist at the N-methyl-D-aspartate (NMDA) glutamatergic receptor, enhances the efficacy of behavior therapy for obsessive-compulsive disorder (OCD).

METHOD:

A randomized, double-blind, placebo-controlled trial investigating D-cycloserine versus placebo augmentation of behavior therapy was conducted in 23 OCD patients. Patients first underwent a diagnostic interview and pretreatment evaluation, followed by a psychoeducational/treatment planning session. Then they received 10 behavior therapy sessions. Treatment sessions were conducted twice per week. One hour before each of the behavior therapy sessions, the participants received either D-cycloserine, 100 mg, or a placebo.

RESULTS:

Relative to the placebo group, the D-cycloserine group's OCD symptoms were significantly more improved at mid-treatment, and the D-cycloserine group's depressive symptoms were significantly more improved at posttreatment.

CONCLUSIONS:

These data provide support for the use of D-cycloserine as an augmentation of behavior therapy for OCD and extend findings in animals and other human disorders suggesting that behavior therapy acts by way of long-term potentiation of glutamatergic pathways and that the effects of behavior therapy are potentiated by an NMDA agonist.

Comment in

PMID:
18245177
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Write to the Help Desk